These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 1602798)

  • 1. Correlation of endogenous acetyl-ser-asp-lys-pro plasma levels in mice and the kinetics of pluripotent hemopoietic stem cells entry into the cycle after cytosine arabinoside treatment: fundamental and clinical aspects.
    Frindel E; Masse A; Pradelles P; Volkov L; Rigaud M
    Leukemia; 1992 Jun; 6(6):599-601. PubMed ID: 1602798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human placental low molecular weight factors inhibit the entry into cell cycle of murine pluripotent stem cells.
    Lopez M; Wdzieczak-Bakala J; Pradelles P; Frindel E
    Leukemia; 1991 Mar; 5(3):270-2. PubMed ID: 2013983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated granulocytes oxidize the endogenous stem cell inhibitory peptide pGlu-Glu-Asp-Cys-Lys (pEEDCK) to the stimulatory dimer: a redox-mediated mechanism for demand-induced hematopoietic regulation.
    Paukovits WR; Paukovits JB; Moser MH; Konstantinov S; Schulte-Hermann R
    Exp Hematol; 1998 Aug; 26(9):851-8. PubMed ID: 9694506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The physiological role of the endogenous colony forming units-spleen (CFU-S) inhibitor acetyl-N-Ser-Asp-Lys-Pro (AcSDKP).
    Frindel E; Monpezat JP
    Leukemia; 1989 Oct; 3(10):753-4. PubMed ID: 2779291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Goralatide (AcSDKP) selectively protects murine hematopoietic progenitors and stem cells against hyperthermic damage.
    Wierenga PK; Konings AW
    Exp Hematol; 1996 Feb; 24(2):246-52. PubMed ID: 8641348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The tetrapeptide AcSDKP reduces the sensitivity of murine CFU-MK and CFU-GM progenitors to aracytine in vitro and in vivo.
    Aidoudi S; Guigon M; Drouet V; Caen JP; Han ZC
    Int J Hematol; 1998 Aug; 68(2):145-55. PubMed ID: 9803673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The molecular specificity of action of the tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) in the control of hematopoietic stem cell proliferation.
    Robinson S; Lenfant M; Wdzieczak-Bakala J; Riches A
    Stem Cells; 1993 Sep; 11(5):422-7. PubMed ID: 8241953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lisinopril, an angiotensin I-converting enzyme inhibitor, prevents entry of murine hematopoietic stem cells into the cell cycle after irradiation in vivo.
    Rousseau-Plasse A; Wdzieczak-Bakala J; Lenfant M; Ezan E; Genet R; Robinson S; Briscoe T; Melville J; Riches A
    Exp Hematol; 1998 Oct; 26(11):1074-9. PubMed ID: 9766448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of acetyl-n-ser-asp-lys-pro (AcSDKP) on hematopoietic progenitor cells in short-term and long-term murine bone marrow cultures.
    Jackson JD; Yan Y; Ewel C; Talmadge JE
    Exp Hematol; 1996 Feb; 24(3):475-81. PubMed ID: 8599978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catabolism of the tetrapeptide N-Ac-Ser-Asp-Lys-Pro (AcSDKP), an inhibitor of hematopoietic stem cell (CFU-S) proliferation, following in vitro incubation with hematopoietic tissues from normal and leukemic mice.
    Wdzieczak-Bakala J; Grillon C; Robinson S; Riches A; Carde P; Lenfant M
    Bull Cancer; 1993 May; 80(5):391-6. PubMed ID: 8173192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of the adherence of hematopoietic stem cells to mouse bone marrow-derived stromal cell line MS-1-T by a tetrapeptide acetyl-N-Ser-Asp-Lys-Pro.
    Lenfant M; Itoh K; Sakoda H; Sotty D; Sasaki NA; Wdzieczak-Bakala J; Mori KJ
    Exp Hematol; 1989 Sep; 17(8):898-902. PubMed ID: 2767182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological activities of tetrapeptide AcSDKP on hemopoietic cell binding to the stromal cell in vitro.
    Aizawa S; Toyama K; Mori KJ; Frindel E
    Exp Hematol; 1992 Aug; 20(7):896-9. PubMed ID: 1628708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of analogues of the tetrapeptide N-Acetyl-Ser-Asp-Lys-Pro (AcSDKP), an inhibitor of primitive haematopoietic cell proliferation.
    Thierry J; Grillon C; Gaudron S; Potier P; Riches A; Wdzieczak-Bakala J
    J Pept Sci; 2001 May; 7(5):284-93. PubMed ID: 11428549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of CFU-S entry into cell cycle after irradiation and drug treatment.
    Guigon M; Frindel E
    Biomedicine; 1978 Jul; 29(5):176-8. PubMed ID: 719133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro effect of acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) analogs resistant to angiotensin I-converting enzyme on hematopoietic stem cell and progenitor cell proliferation.
    Gaudron S; Grillon C; Thierry J; Riches A; Wierenga PK; Wdzieczak-Bakala J
    Stem Cells; 1999; 17(2):100-6. PubMed ID: 10195570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tetrapeptide AcSDKP, an inhibitor of the cell-cycle status for normal human hematopoietic progenitors, has no effect on leukemic cells.
    Bonnet D; Césaire R; Lemoine F; Aoudjhane M; Najman A; Guigon M
    Exp Hematol; 1992 Feb; 20(2):251-5. PubMed ID: 1544396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of a negative regulator of cell proliferation (AcSDKP) are increased in certain human haemopathies.
    Liozon E; Pradelles P; Venot J; Rigaud M; Cransac M; Bordessoule D; Frindel E
    Leukemia; 1993 Jun; 7(6):808-12. PubMed ID: 8501976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mechanism of action of the tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) in the control of haematopoietic stem cell proliferation.
    Robinson S; Lenfant M; Wdzieczak-Bakala J; Melville J; Riches A
    Cell Prolif; 1992 Nov; 25(6):623-32. PubMed ID: 1457609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On control of the hematopoietic cell proliferation.
    Necas E; Sefc L; Znojil V
    Stem Cells; 1993 Jul; 11(4):319-25. PubMed ID: 8401255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Further purification of a CFU-S inhibitor: in vivo effects after cytosine arabinoside treatment.
    Wdzieczak-Bakala J; Guigon M; Lenfant M; Frindel E
    Biomed Pharmacother; 1983; 37(9-10):467-71. PubMed ID: 6689548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.